We used an oral form of CKD-516 and designed a combination experiment with sorafenib. BLI tumor viability measurement showed CKD-516 was effective in combination with sorafenib, but there was only a slight improvement when treated alone. By MRI, the CKD-516 group showed notable intratumoral hemorrhage and central necrosis from the early stage of treatment. By IHC, CKD-516 was advantageous in collapsing blood vessels in tumor tissue, and was more effective when treated in combination with sorafenib. Therefore, oral CKD-516 was advantageous over sorafenib in terms of vascular disrupting ability, and combination of CKD-516 with sorafenib reduced the rebound phenomenon.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords